Glial fibrillary acidic protein and neurofilament light chain as biomarkers in pediatric multiple sclerosis-Reference-Cited by-同舟云学术

Glial fibrillary acidic protein and neurofilament light chain as biomarkers in pediatric multiple sclerosis

Published:2024-07 Issue:3 Volume:10 Page:
ISSN:2055-2173
Container-title:Multiple Sclerosis Journal - Experimental, Translational and Clinical
language:en
Short-container-title:Multiple Sclerosis Journal - Experimental, Translational and Clinical

Author:

Saucier Laura¹²,Healy Brian C³⁴,Saxena Shrishti⁵,Sanon Eunnindy⁵,Chitnis Tanuja⁶^ORCID

Affiliation:

1. Translational Neuroimmunology Research Center (TNRC), Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA;

2. Mass General Brigham Pediatric MS Center, Massachusetts General Hospital, Boston, MA, USA; Brigham MS Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA;

3. Brigham MS Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA;

4. Harvard Medical School, Boston, MA, USA; Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA;

5. Translational Neuroimmunology Research Center (TNRC), Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Brigham MS Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA;

6. Translational Neuroimmunology Research Center (TNRC), Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Mass General Brigham Pediatric MS Center, Massachusetts General Hospital, Boston, MA, USA; Brigham MS Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA

Abstract

Background Serum neurofilament light chain (sNfL) is a marker of neuroaxonal injury, and serum glial fibrillary acidic protein (sGFAP) reflects reactive astrogliosis. In adult multiple sclerosis (MS), sNfL correlates with relapsing disease activity while sGFAP correlates with progressive disease. Objectives We evaluate sNfL and sGFAP as biomarkers in pediatric-onset MS (POMS) compared to pediatric healthy controls (PHC), and correlations with the disease course. Methods In this single-center observational cross-sectional study, we extracted data from a longitudinal database and measured NfL and GFAP from bio-banked serum using single-molecule array technology. Results The analysis included 61 POMS patients and 45 PHC. Controlling for age and BMI, sNfL was 414% higher and sGFAP was 42.3% higher in POMS. Disability (EDSS) is associated with higher sNfL ( β = 0.32, p = 0.002) and higher sGFAP ( β = 0.11, p = 0.03). sNfL is associated with MRI lesion burden, recent disease activity ( β =0.95, p < 0.001), and untreated status ( β = 0.5, p = 0.006). Conclusion sNfL and sGFAP are elevated in POMS compared to PHC. Both biomarkers are associated with clinical disability. Elevated sGFAP may reflect early neurodegeneration in POMS, while sNfL reflects disease activity and DMT response. Elevated sNfL among some clinically and radiographically stable POMS patients suggests ongoing neuroaxonal injury with a potential role for sNfL monitoring disease stability.

Funder

National Multiple Sclerosis Society

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/20552173241274567

Reference35 articles.

1. Multiple sclerosis

2. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States

3. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years

4. Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis

5. Natural History of Multiple Sclerosis with Childhood Onset